Skip to main navigation
LinkedIn Twitter
  • Investors
  • Careers
Outlook Therapeutics, Inc. Logo
  • About
    • Overview
    • Senior Leadership
    • Board of Directors
  • Pipeline
    • ONS-5010 Overview
    • ONS-5010 Clinical Progress
  • News
  • Contact

In the News

Home / Investors / News & Events / In the News

In the News

Date Title
December 9, 2020
Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab
October 6, 2020
Spotlight Q&A: Outlook Therapeutics - Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval
January 7, 2019
Proactive Investors interview with Outlook Therapeutics CEO Larry Kenyon
  • Investor Overview
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Other Shareholder Information
  • Financial Information
    • SEC Filings
  • Analyst Coverage
  • News & Events
    • Press Releases
    • Events
    • In the News
    • Presentations
  • Corporate Governance
    • Governance Highlights
    • Senior Leadership
    • Board of Directors
    • Committee Composition
  • Information Request
  • Print Page Print Page
  • Email Page Email Page
  • RSS Feeds RSS Feeds
  • Email Alerts Email Alerts
  • Contact IR Contact IR
© 2021 Outlook Therapeutics, Inc.
Privacy Policy | Disclaimer